Actively Recruiting
Study of Brigatinib Treatment for Children and Young Adults With ALK Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors
Led by Princess Maxima Center for Pediatric Oncology · Updated on 2025-12-05
65
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating brigatinib, a second-generation oral tyrosine kinase inhibitor, in pediatric and young adult patients aged 1 to 25 years with ALK-positive anaplastic large cell lymphoma ALCL, inflammatory myofibroblastic tumors IMT, or other solid tumors. This open-label Phase I-II study aims to determine the recommended dose of brigatinib when used alone, and to assess its pharmacokinetics, long-term safety, and effectiveness in these patients. The study has two parts Phase 1 involves dose escalation using a rolling-6 design to find the maximum tolerated dose or recommended Phase 2 dose, focusing mainly on patients 18 years or younger. Phase 2 expands to evaluate safety and clinical activity in two groups one with ALK-positive IMT and another with ALK-positive ALCL, with planned sample sizes of 12 and 22 patients respectively. Patients receive brigatinib orally, and dosing decisions consider pediatric pharmacokinetics and toxicity. Participants will be monitored over 2 years, with assessments including evaluation of dose tolerance, drug pharmacokinetics, tumor response by RECIST criteria for IMT, and event-free survival for ALCL. Safety and organ function tests, cardiac monitoring, and pregnancy tests are part of the evaluations. The study also requires adherence to contraception guidelines and follow-up for long-term outcomes to understand brigatinibs role in these cancers.
CONDITIONS
Brief Title
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Research Team
M
Maaike Boonstra
G
Gertruud Bakker
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here